Research programme: analgesic transdermal - ShireAlternative Names: SPD 491
Latest Information Update: 07 Mar 2008
At a glance
- Originator Shire plc
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 21 Feb 2008 Discontinued - Preclinical for Pain in USA (Transdermal)
- 20 Feb 2007 Preclinical trials in Pain in USA (Transdermal)